{
    "clinical_study": {
        "@rank": "19950", 
        "arm_group": {
            "arm_group_label": "Tetrabenazine withdrawal", 
            "arm_group_type": "Experimental", 
            "description": "Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently taking the medication."
        }, 
        "brief_summary": {
            "textblock": "Tetrabenazine has been shown to improve gating of abnormal visual stimuli and improve\n      postural stability in Huntington disease (HD) patients as measured by computerized dynamic\n      posturography testing. This study aims to elucidate whether partial dopaminergic depletion\n      via low dose tetrabenazine has a similar effect on masking out of abnormal visual stimuli on\n      the Stroop interference test."
        }, 
        "brief_title": "Effect of Tetrabenazine on Stroop Interference in HD", 
        "condition": "Huntington Disease", 
        "condition_browse": {
            "mesh_term": "Huntington Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Established diagnosis of Huntington disease by movement disorders expert\n\n          -  Patients currently taking tetrabenazine.\n\n          -  Patients should not have taken dopamine receptor blocking medication for at least\n             three days\n\n        Exclusion Criteria:\n\n        -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01834911", 
            "org_study_id": "L-10,830"
        }, 
        "intervention": {
            "arm_group_label": "Tetrabenazine withdrawal", 
            "description": "Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.", 
            "intervention_name": "Tetrabenazine withdrawal", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Tetrabenazine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Huntington disease", 
            "HD", 
            "tetrabenazine", 
            "Stroop"
        ], 
        "lastchanged_date": "April 15, 2013", 
        "link": {
            "description": "Dr. Robert Fekete bio", 
            "url": "http://www.nymc.edu/neurology/fekete.htm"
        }, 
        "location": {
            "contact": {
                "last_name": "Katherine Becker, LMSW", 
                "phone": "212-360-3711"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Terence Cardinal Cooke Health Care Center"
            }, 
            "investigator": [
                {
                    "last_name": "Robert Fekete, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Silky Singh, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effect of Tetrabenazine on Stroop Interference in Huntington Disease", 
        "overall_contact": {
            "email": "robert_fekete@nymc.edu", 
            "last_name": "Robert Fekete, MD", 
            "phone": "9145944293"
        }, 
        "overall_contact_backup": {
            "last_name": "Robert Fekete, MD", 
            "phone": "9143451313"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Participants will have Stroop Visual Interference Scores measured while OFF tetrabenazine for at least 3 days. Two doses of 12.5 mg tetrabenazine will be subsequently administered: first dose just after the Stroop test and second dose 3 hours later. Stroop Visual Interference Scores will be measured again in the ON state, 6 hours after the initial OFF measurement.", 
            "measure": "Change in Stroop Interference Score", 
            "safety_issue": "No", 
            "time_frame": "6 hours"
        }, 
        "reference": {
            "PMID": "22621818", 
            "citation": "Fekete R, Davidson A, Ondo WG, Cohen HS. Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients. Parkinsonism Relat Disord. 2012 Aug;18(7):896-8. doi: 10.1016/j.parkreldis.2012.04.029. Epub 2012 May 22."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01834911"
        }, 
        "responsible_party": {
            "investigator_affiliation": "New York Medical College", 
            "investigator_full_name": "Robert Fekete", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "New York Medical College", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "New York Medical College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}